Article
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.
Cell communication and signaling : CCS - 11 Apr 2023
Li Yufeng, Mao Tianyu, Wang Jing, Zheng Hongrui, Hu Ziyi, Cao Pingping, Yang Suisui, Zhu Lingyun, Guo Shunyao, Zhao Xinfei, Tian Yue, Shen Hua, Lin Fan
Abstract excerpt
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC). The life quality and survival of this subgroup of patients were constantly improving owing to the continuous iteration and optimization of EGFR-TKI. Osimertinib, an oral, third-generation, irreversible EGFR-TKI, was initially approved for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.